Sandra and Edward Meyer Cancer Center

You are here


Taking Target

The immune system has a tough time targeting cancer cells because they often find ways to alter their make-up or microenvironment to avoid detection. To overcome this, researchers at Meyer Cancer Center and elsewhere have found ways to help the immune system recognize cancer cells and strengthen its response so that it will destroy them. Find out about the innovative ways that physicians and scientists at Weill Cornell Medicine and NewYork-Presbyterian are harnessing patients' own bodies to target their tumors.


Renowned radiation oncologist Sylvia Formenti, M.D., of the Meyer Cancer Center, is transforming tumors via immunotherapy

From foe to friend: Transforming tumors into personalized vaccines

Radiation has long been a pillar of cancer care, alongside surgery and chemotherapy. But what if it could be used in a new way - to trigger a set of immune responses that transform tumors into killing machines, a type of in situ vaccine? Renowned radiation oncologist Sylvia Formenti, M.D., and Sandra Demaria, M.D., are expanding and transforming the field of immunotherapy.

Blood cancers

Meyer Cancer Center researchers are developing targeted immunotherapy for patients with AML

Teaming up to translate AML discoveries into novel immunotherapy

Weill Cornell Medicine and Cellectis have entered into a strategic translational research alliance to accelerate the development of a targeted immunotherapy for patients with acute myelogenous leukemia (AML), a deadly blood cancer. The company is working with Gail Roboz, M.D., as they develop gene edited CAR-T cell product candidates, a special kind of immune cell that includes an antibody-derived receptor.

Meyer Cancer Center researchers are developing targeted immunotherapy to attack leukemia stem cells

Solving the leukemia stem cell conundrum

Monica Guzman, Ph.D., and Duane Hassane, Ph.D., are combatting "minimal residual disease," the bane of leukemia treatment, by targeting leukemia stem cells using CAR-T cells engineered to seek out a protein marker they have identified on the surface of those cells.

Immunotherapy is an exciting new frontier in blood cancers like lymphoma

Immune checkpoint inhibition an ‘important new frontier’ in lymphoma

“This is very exciting and it is an important new frontier, just as it is in solid tumors,” says renowned lymphoma expert John P. Leonard, M.D., in a review of the role of immunotherapy — specifically immune checkpoint inhibitors ― in the treatment of blood cancers.

Pancreatic cancer

Immunotherapy expert Douglas Fearon, M.D., of Meyer Cancer Center, is exploring new ways to treat pancreatic cancer

Eliminating T cell barriers in pancreatic cancer patients

Immunotherapeutic approaches that have worked in other cancer types have not been effective against pancreatic cancer. Douglas Fearon, M.D., is hoping to change that by exploring ways to eliminate T cell barriers in pancreatic cancer patients.

Ovarian cancer

Weill Cornell Dean Laurie Glimcher is leading immunotherapy research into ovarian cancer

Glimcher lab identifies immune trigger in ovarian cancer

Ovarian cancer shuts down immune system cells that would otherwise act as a first line of defense against the deadly tumor. A team led by Dean Laurie Glimcher, M.D., has identified a key gene that can be targeted to restore dendritic cell function and trigger robust immune responses against the difficult-to-treat cancer

Prostate cancer

Prostate cancer expert Mark Rubin, M.D., of Meyer Cancer Center discusses immunotherapy in genitourinary cancers

Immunotherapy in genitourinary cancers

Is there anything that can be done to increase the viability of immunotherapy in prostate cancer? Mark A Rubin, M.D., discusses the issue of "mutation load" in various genitourinary cancers.